The bladder cancer genome; chromosomal changes as prognostic makers, opportunities, and obstacles

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 4, 2012, Pages 533-540

  Höglund, Mattias ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Bladder cancer; Chromosomal changes; Prognostic markers

Indexed keywords

BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER GENETICS; CANCER GRADING; CANCER GROWTH; CANCER STAGING; CARCINOMA IN SITU; CHROMOSOME 9; CHROMOSOME ABERRATION; CHROMOSOME LOSS; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; DYSPLASIA; GENETIC ASSOCIATION; GENOME ANALYSIS; HETEROZYGOSITY LOSS; HUMAN; HYPERPLASIA; PRECANCER; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; REVIEW;

CHROMOSOME ABERRATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LOSS OF HETEROZYGOSITY; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84862990351     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.04.001     Document Type: Review

References (44)

1. An international system for human cytogenetic nomenclature Ag 2009, ISCN. L.G. Shaffer, M.L. Slovak, L.J. Campbell, S. Karger (Eds.).
2. Fadl-Elmula I. Chromosomal changes in uroepithelial carcinomas. Cell Chromosome 2005, 7. 4:1.
3. Mitelman Database of chromosome aberrations and gene fusions in cancer 2010, http://cgap.nci.nih.gov/Chromosomes/Mitelman, F. Mitelman, B. Johansson, F. Mertens (Eds.).
4. Höglund M., Säll T., Heim S., et al. Identification of cytogenetic subgroups and karyotypic pathways in transitional cell carcinoma. Cancer Res 2001, 61:8241-8246.
5. Kallioniemi A., Kallioniemi O.P., Citro G., et al. Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Genes Chromosomes Cancer 1995, 12:213-219.
6. Voorter C., Joos S., Bringuier P.P., et al. Detection of chromosomal imbalances in transitional cell carcinoma of the bladder by comparative genomic hybridization. Am J Pathol 1995, 146:1341-1354.
7. Richter J., Jiang F., Görög J.P., et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 1997, 57:2860-2864.
8. Zhao J., Richter J., Wagner U., et al. Chromosomal imbalances in noninvasive papillary bladder neoplasms (pTa). Cancer Res 1999, 59:4658-4661.
9. Simon R., Bürger H., Brinkschmidt C., et al. Chromosomal aberrations associated with invasion in papillary superficial bladder cancer. J Pathol 1998, 185:345-351.
10. Richter J., Beffa L., Wagner U., et al. Patterns of chromosomal imbalances in advanced urinary bladder cancer detected by comparative genomic hybridization. Am J Pathol 1998, 153:1615-1621.
11. Richter J., Wagner U., Schraml P., et al. Chromosomal imbalances are associated with a high risk of progression in early invasive (pT1) urinary bladder cancer. Cancer Res 1999, 59:5687-5691.
12. Prat E., del Rey J., Ponsa I., et al. Comparative genomic hybridization analysis reveals new different subgroups in early-stage bladder tumors. Urology 2010, 75:347-355.
13. Veltman J.A., Fridlyand J., Pejavar S., et al. Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res 2003, 63:2872-2880.
14. Hurst C.D., Fiegler H., Carr P., et al. High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization. Oncogene 2004, 23:2250-2263.
15. Blaveri E., Brewer J.L., Roydasgupta R., et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 2005, 11:7012-7022.
16. Heidenblad M., Lindgren D., Jonson T., et al. Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors. BMC Med Genomics 2008, 1:3.
17. Primdahl H., Wikman F.P., von der Maase H., et al. Allelic imbalances in human bladder cancer: genome-wide detection with high-density single-nucleotide polymorphism arrays. J Natl Cancer Inst 2002, 94:216-223.
18. Hoque M.O., Lee C.C., Cairns P., et al. Genome-wide genetic characterization of bladder cancer: A comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res 2003, 63:2216-2222.
19. Koed K., Wiuf C., Christensen L.L., et al. High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors. Cancer Res 2005, 65:34-45.
20. Chan M.W., Hui A.B., Yip S.K., et al. Progressive increase of genetic alteration in urinary bladder cancer by combined allelotyping analysis and comparative genomic hybridization. Int J Oncol 2009, 34:963-970.
21. Hartmann A., Moser K., Kriegmair M., et al. Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 1999, 154:721-727.
22. Krause S., Feil G., Beiter T., et al. Examination of tumorigenesis of precursor lesions in bladder cancer by in situ hybridization. Urol Int 2004, 72:118-122.
23. Zieger K., Marcussen N., Borre M., et al. Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of 2 major pathways in bladder cancer development. Int J Cancer 2009, 125:2095-2103.
24. Hartmann A., Schlake G., Zaak D., et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 2002, 62:809-818.
25. Chow N.H., Cairns P., Eisenberger C.F., et al. Papillary urothelial hyperplasia is a clonal precursor to papillary transitional cell bladder cancer. Int J Cancer 2000, 89:514-518.
26. Obermann E.C., Junker K., Stoehr R., et al. Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses. J Pathol 2003, 199:50-57.
27. van Oers J.M., Adam C., Denzinger S., et al. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int J Cancer 2006, 119:1212-1215.
28. Gudjónsson S., Isfoss B.L., Hansson K., et al. The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol 2008, 54:402-408.
29. Zellweger T., Benz G., Cathomas G., et al. Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer. Int J Cancer 2006, 119:1660-1665.
30. Cai T., Nesi G., Dal Canto M., et al. Loss of heterozygosis on IFN-alpha locus is a prognostic indicator of bacillus Calmette-Guerin response for non-muscle-invasive bladder cancer. J Urol 2010, 183:1738-1743.
31. Eguchi S., Yamamoto Y., Sakano S., et al. The loss of 8p23.3 is a novel marker for predicting progression and recurrence of bladder tumors without muscle invasion. Cancer Genet Cytogenet 2010, 200:16-22.
32. Tzai T.S., Chen H.H., Chan S.H., et al. Clinical significance of allelotype profiling for urothelial carcinoma. Urology 2003, 62:378-384.
33. Uchida A., Tachibana M., Miyakawa A., et al. Microsatellite analysis in multiple chromosomal regions as a prognostic indicator of primary bladder cancer. Urol Res 2000, 28:297-303.
34. Jin Y., Stewénius Y., Lindgren D., et al. Distinct mitotic segregation errors mediate chromosomal instability in aggressive urothelial cancers. Clin Cancer Res 2007, 13:1703-1712.
35. Gisselsson D., Pettersson L., Höglund M., et al. Chromosomal breakage-fusion-bridge events cause genetic intratumor heterogeneity. Proc Natl Acad Sci USA 2000, 97:5357-5362.
36. Yamamoto Y., Matsuyama H., Furuya T., et al. Centrosome hyperamplification predicts progression and tumor recurrence in bladder cancer. Clin Cancer Res 2004, 10:6449-6455.
37. van Tilborg A.A., de Vries A., de Bont M., et al. Molecular evolution of multiple recurrent cancers of the bladder. Hum Mol Genet 2000, 9:2973-2980.
38. Lindgren D., Gudjonsson S., Jee K.J., et al. Recurrent and multiple bladder tumors show conserved expression profiles. BMC Cancer 2008, 8:183.
39. Cianciulli A.M., Leonardo C., Guadagni F., et al. Genetic instability in superficial bladder cancer and adjacent mucosa: An interphase cytogenetic study. Hum Pathol 2003, 34:214-221.
40. Steidl C., Simon R., Bürger H., et al. Patterns of chromosomal aberrations in urinary bladder tumours and adjacent urothelium. J Pathol 2002, 198:115-120.
41. Baud E., Catilina P., Boiteux J.P., et al. Human bladder cancers and normal bladder mucosa present the same hot spot of heterozygous chromosome-9 deletion. Int J Cancer 1998, 77:82182-82184.
42. Muto S., Horie S., Takahashi S., et al. Genetic and epigenetic alterations in normal bladder epithelium in patients with metachronous bladder cancer. Cancer Res 2000, 60:4021-4025.
43. Chaturvedi V., Li L., Hodges S., et al. Superimposed histologic and genetic mapping of chromosome 17 alterations in human urinary bladder neoplasia. Oncogene 1997, 14:2059-2070.
44. Czerniak B., Chaturvedi V., Li L., et al. Superimposed histologic and genetic mapping of chromosome 9 in progression of human urinary bladder neoplasia: Implications for a genetic model of multistep urothelial carcinogenesis and early detection of urinary bladder cancer. Oncogene 1999, 18:1185-1196.